OCUL vs ALDX vs KALA vs RXST

For growth investors, RxSight, Inc.

(RXST) is the stronger pick with -3. 9% revenue growth year-over-year, versus -18. 7% for Ocular Therapeutix, Inc. (OCUL). Analysts rate Ocular Therapeutix, Inc. (OCUL) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ocular Therapeutix, Inc.

(OCUL) delivered a total return of -40. 4%, compared to -100. 0% for KALA BIO, Inc. (KALA). Over 10 years, the gap is even starker: OCUL returned -10. 6% versus KALA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ocular Therapeutix, Inc.

(OCUL) is the lower-risk stock at 1. 27β versus KALA BIO, Inc. 's 2. 09β — meaning KALA is approximately 65% more volatile than OCUL relative to the S&P 500. On balance sheet safety, RxSight, Inc. (RXST) carries a lower debt/equity ratio of 4% versus 3% for KALA BIO, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), RxSight, Inc.

(RXST) is pulling ahead at -3. 9% versus -18. 7% for Ocular Therapeutix, Inc. (OCUL). On earnings-per-share growth, the picture is similar: KALA BIO, Inc. grew EPS 59. 8% year-over-year, compared to -46. 9% for Aldeyra Therapeutics, Inc.. Over a 3-year CAGR, RXST leads at 40. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aldeyra Therapeutics, Inc.

(ALDX) is the more profitable company, earning 0. 0% net margin versus -141. 1% for KALA BIO, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALDX leads at 0. 0% versus -150. 6% for KALA. At the gross margin level — before operating expenses — OCUL leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for KALA: 21861.

5% to $18. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ocular Therapeutix, Inc.

(OCUL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 27)). KALA BIO, Inc. (KALA) carries a higher beta of 2. 09 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OCUL: -10. 6%, KALA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.